Stocks & Investing
Tue, March 5, 2024
[ Tue, Mar 05th 2024
] - WOPRAI
Fri, March 1, 2024
[ Fri, Mar 01st 2024
] - WOPRAI
Fri, February 16, 2024
[ Fri, Feb 16th 2024
] - WOPRAI
Thu, February 15, 2024
[ Thu, Feb 15th 2024
] - WOPRAI
Thu, October 12, 2023
[ Thu, Oct 12th 2023
] - WOPRAI
Thu, February 2, 2023
[ Thu, Feb 02nd 2023
] - WOPRAI
Wed, November 30, 2022
[ Wed, Nov 30th 2022
] - WOPRAI
Fri, October 21, 2022
[ Fri, Oct 21st 2022
] - WOPRAI
Wed, July 27, 2022
[ Wed, Jul 27th 2022
] - WOPRAI
Tue, August 10, 2021
[ Tue, Aug 10th 2021
] - WOPRAI
Fri, July 17, 2020
[ Fri, Jul 17th 2020
] - WOPRAI
John Sourbeer Maintained (AKYA) at Strong Buy with Increased Target to $7.5 on, Mar 5th, 2024
John Sourbeer of UBS, Maintained "Akoya Biosciences, Inc." (AKYA) at Strong Buy with Increased Target from $7 to $7.5 on, Mar 5th, 2024.
John has made no other calls on AKYA in the last 4 months.
There are 3 other peers that have a rating on AKYA. Out of the 3 peers that are also analyzing AKYA, 1 agrees with John's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Subbu Nambi of "Guggenheim" Initiated at Hold on, Thursday, December 14th, 2023
These are the ratings of the 2 analyists that currently disagree with John
- David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $8 on, Monday, November 13th, 2023
- Mason Carrico of "Stephens & Co." Maintained at Buy with Decreased Target to $9 on, Monday, November 13th, 2023
